Jazz Pharmaceuticals plc Debt Securities, Available-for-sale
Jazz Pharmaceuticals plc (JAZZ) had Debt Securities, Available-for-sale of $2.44 billion as of 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2026-02-24
- 2025-12-31: Debt Securities, Available-for-sale $2.44B.
- 2025-09-30: Debt Securities, Available-for-sale $2.05B.
- 2025-06-30: Debt Securities, Available-for-sale $1.67B.
- 2025-03-31: Debt Securities, Available-for-sale $2.57B.
| Period end | Debt Securities, Available-for-sale |
|---|---|
| 2025-12-31 | $2.44B 10-K · filed 2026-02-24 |
| 2025-09-30 | $2.05B 10-Q · filed 2025-11-05 |
| 2025-06-30 | $1.67B 10-Q · filed 2025-08-06 |
| 2025-03-31 | $2.57B 10-Q · filed 2025-05-07 |
| 2024-12-31 | $2.99B 10-K · filed 2026-02-24 |
| 2024-09-30 | $2.62B 10-Q · filed 2024-11-07 |
| 2024-06-30 | $1.98B 10-Q · filed 2024-08-01 |
| 2024-03-31 | $1.82B 10-Q · filed 2024-05-02 |
| 2023-12-31 | $1.63B 10-K · filed 2025-02-26 |
| 2023-09-30 | $1.59B 10-Q · filed 2023-11-08 |
| 2023-06-30 | $1.36B 10-Q · filed 2023-08-09 |
| 2023-03-31 | $1.17B 10-Q · filed 2023-05-10 |
| 2022-12-31 | $881.48M 10-K · filed 2024-02-28 |
| 2022-09-30 | $899.36M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $771.26M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $490.83M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $591.45M 10-K · filed 2023-03-01 |
| 2021-09-30 | $671.78M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $891.40M 10-Q · filed 2021-08-03 |
| 2021-03-31 | $2.43B 10-Q · filed 2021-05-04 |
| 2020-12-31 | $2.13B 10-K · filed 2022-03-01 |
| 2020-09-30 | $1.92B 10-Q · filed 2020-11-02 |
| 2020-06-30 | $1.70B 10-Q · filed 2020-08-04 |
| 2020-03-31 | $981.60M 10-Q · filed 2020-05-05 |
| 2019-12-31 | $1.08B 10-K · filed 2021-02-23 |
| 2019-09-30 | $1.07B 10-Q · filed 2019-11-05 |
| 2019-06-30 | $882.74M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $832.47M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $824.62M 10-K · filed 2020-02-25 |
| 2018-09-30 | $1.06B 10-Q · filed 2018-11-06 |
| 2018-06-30 | $815.08M 10-Q · filed 2018-08-07 |
| 2017-12-31 | $601.03M 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |